Capstone Investments Starts Salix Pharmaceuticals (SLXP) at Buy, Price Target $51
Tweet Send to a Friend
Capstone Investments initiates coverage on Salix Pharmaceuticals (NASDAQ: SLXP) with a Buy rating and a price target of $51.
This article: 186 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 186 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
